Symptoms of appendiceal cancer

Update Date: 2024-03-04 Source: Network

summary

Cancer has been a serious threat to our lives. In our hearts, cancer is a terrible malignant tumor, so many people always doubt whether they have cancer. It can be seen that the diagnosis of cancer is very vague for ordinary people, so it is very important for the clinical diagnosis of cancer. Doctors in the choice of cancer diagnosis, the general situation is the first imaging examination, if there is doubt, then pathological examination confirmed. Most of the malignant tumors in the appendix are carcinoid. Carcinoid is a kind of malignant tumor of gastrointestinal tract. The tumor is small and grows slowly. The symptoms are often not obvious, and metastasis can also occur.

Symptoms of appendiceal cancer

Carcinoid is rare. If the release of peptide amine hormone is secreted by carcinoid tumor, patients will have abdominal pain, diarrhea, asthma, hepatomegaly and other symptoms, which is called carcinoid syndrome in medicine. Appendicitis is rare. The average age of onset was 40 years.

Appendiceal carcinoid has low malignancy, small size, less than 2 cm in diameter, and rarely metastasis. Appendiceal carcinoid mostly grows in 1 / 3 from the top of the appendix, so it is not easy to block the appendiceal lumen, and rarely causes appendicitis. If carcinoid grows in 1 / 3 of the appendix, appendicitis occurs due to blockage of the lumen.

During the operation, because of the small size of the tumor, it is not easy to find or mistakenly think of the fecal calculus. The correct diagnosis can be made only after pathological examination. Appendiceal carcinoid can also have the performance of appendiceal perforation, usually found after surgery is appendiceal carcinoid perforation.

matters needing attention

Chemotherapy drugs include 5-fluorouracil, capecitabine, oxaliplatin, irinotecan, bevacizumab, cetuximab, panimab and other drugs. The commonly used chemotherapy programs include FOLFOX, XELOX, FOLFIRI, etc. on the basis of chemotherapy, bevacizumab, cetuximab, panimab and other targeted drugs are combined as appropriate.